Shattuck Labs
Yahoo Finance • 8 days ago
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily recept... Full story
Yahoo Finance • 22 days ago
Regency Centers' Series A Preferred Stock Shares Cross 6.5% Yield Mark
In trading on Monday, shares of Regency Centers Corp's 6.250% Series A Cumulative Redeemable Preferred Stock (Symbol: REGCP) were yielding above the 6.5% mark based on its quarterly dividend (annualized to $1.5625), with shares changing ha... Full story
Yahoo Finance • last month
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER... Full story
Yahoo Finance • last month
Top movers analysis one hour before the close of the markets on 2025-09-03: top gainers and losers in today's session.
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT STI [https://www.chartmill.com/stock/quote/STI/profile] 86.59% SOLIDION TECHN... Full story
Yahoo Finance • last month
Wednesday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT STI [https://www.chartmill.com/sto... Full story
Yahoo Finance • last month
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equival... Full story
- IRON
Mentioned:
Yahoo Finance • 2 months ago
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first parti... Full story
Yahoo Finance • 2 months ago
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2... Full story
Yahoo Finance • 2 months ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change SolarMax Technology Inc. 215,178,273 2.50 1.57 2.025 +1.095 LOBO EV TECH... Full story
Yahoo Finance • 2 months ago
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate pro... Full story
Yahoo Finance • 6 months ago
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily recep... Full story
Yahoo Finance • 6 months ago
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the recept... Full story
Yahoo Finance • 8 months ago
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptor... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medic... Full story
Yahoo Finance • 2 years ago
Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript
Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good morning and welcome to the Shattuck Labs Third Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only m... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
– Positive interim data from Phase 1B clinical trial of SL-172154in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safety profile and encouraging anti-tumor act... Full story
Yahoo Finance • 2 years ago
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic med... Full story
Yahoo Finance • 2 years ago
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting
– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile – AUSTIN, Texas and DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc.... Full story
Yahoo Finance • 2 years ago
The Rosen Law Firm, P.A. Announces Proposed Securities Class Action Settlement on Behalf of Purchasers of the Common Stock of Shattuck Labs, Inc. - STTK
BROOKLYN, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the Eastern District of New York has approved the following announcement of a proposed securities class action... Full story
